GLP - RT3

RT-3 is an investigational triple-agonist medication (targeting GIP, GLP-1, and glucagon receptors) that offers potent,, sustained weight loss, with clinical trials showing up to 24% body weight reduction in 48 weeks. It also can improve metabolic health, enhance glycemic control, reduce liver fat and help lower blood pressure.

Key benefits of retatrutide include:

• Significant Weight Loss: In a 48-week phase 2 study, participants on higher doses lost 22–24% of their body weight, with 60–82% of patients achieving a 15% reduction.

• Triple-Action Mechanism: Unlike dual-agonists (like tirzepatide) or GLP-1s (like semaglutide), it targets GLP-1, GIP, and glucagon receptors, enhancing calorie burning (via glucagon) alongside appetite suppression.

• Metabolic & Cardiovascular Improvement: Retatrutide significantly lowers fasting glucose and HbA1c, improves blood pressure, and reduces waist circumference.

• Reduction of Liver Fat: Studies indicate potential for reversing metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as fatty liver disease.

• Improved Quality of Life: Users reported reduced food cravings and increased, stable energy, with improved physical and emotional well-being